Seattle Genetics (Nasdaq: SGEN ) lists seven drugs on its pipeline page. And there are another 11 clinical-stage drug candidates and quite a few preclinical ones being developed by partners from large companies, such as Roche, Pfizer (NYSE: PFE ) , and Abbott Labs (NYSE: ABT ) , in addition to smaller ones like Progenics Pharmaceuticals (Nasdaq: PGNX ) and Celldex Therapeutics (Nasdaq: CLDX ) But the big bet on Seattle Genetics right now is on its lymphoma drug brentuximab vedotin. The drug is a cell-killing agent attached to a monoclonal antibody that targets cells that express CD30, a marker of Hodgkin lymphoma and anaplastic large cell lymphoma.
